7AY1.F ACTINIUM PHARMAC. DL-001
- Market cap
- EUR 45.0M
- P/E
- 4.3x
- P/B
- 1.56x
- ROE
- 147.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7AY1.F undervalued?
Graham number7AY1.F trades 45.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ACTINIUM PHARMAC. DL-001 fundamental analysis
No fundamental analysis for ACTINIUM PHARMAC. DL-001 yet.
ACTINIUM PHARMAC. DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ACTINIUM PHARMAC. DL-001
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disor…
Full company profileACTINIUM PHARMAC. DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ACTINIUM PHARMAC. DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.14M | 1.03M | 81.0K | 0.00 | 90.0K | 70.0M |
| Operating Income | -25.0M | -34.1M | -51.9M | -42.1M | -36.2M | 43.3M |
| EBITDA | - | -33.4M | -51.1M | -41.3M | -35.4M | 44.2M |
| Net Income | -24.8M | -33.0M | -48.8M | -38.2M | -33.9M | 44.8M |
| EPS | -1.12 | -1.29 | -1.77 | -1.23 | -1.09 | 1.43 |
| Balance Sheet | ||||||
| Total Assets | 80.4M | 114M | 81.4M | 76.9M | 51.8M | 40.2M |
| Total Liabilities | 6.84M | 47.7M | 45.1M | 44.1M | 43.9M | 9.86M |
| Shareholders' Equity | 73.5M | 66.5M | 36.4M | 32.8M | 7.83M | 30.3M |
| Cash & Short-term Investments | 77.8M | 109M | 76.7M | 72.9M | 48.0M | 36.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -20.9M | 8.64M | -47.3M | -33.1M | -24.6M | -22.1M |
| Capital Expenditure | 133K | 366K | 153K | 11.0K | 104K | 960K |
| Free Cash Flow | -21.0M | 8.28M | -47.5M | -33.1M | -24.7M | -23.1M |
| Ratios | ||||||
| ROE | -33.7% | -49.7% | -134.2% | -116.7% | -432.6% | 147.7% |
| ROA | -30.8% | -28.9% | -59.9% | -49.7% | -65.5% | 111.5% |
| Net Profit Margin | -2,165.6% | -3,205.5% | -60,269.1% | - | -37,652.2% | 63.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ACTINIUM PHARMAC. DL-001 dividends
ACTINIUM PHARMAC. DL-001 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:30 on Aug 11, 2020.
Who owns ACTINIUM PHARMAC. DL-001
- Insiders 1.93%
- Institutions 16.65%
- Public & others 81.42%
- Shares outstanding 31.4M
- Free float 31.3M
ACTINIUM PHARMAC. DL-001 company profile
- Company name
- ACTINIUM PHARMAC. DL-001
- Ticker
- 7AY1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 27
- Fiscal year end
- December
- Address
- 100 Park Avenue, New York, NY, United States, 10017
- Phone
- 646 677 3870
- Website
- actiniumpharma.com
About ACTINIUM PHARMAC. DL-001
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
ACTINIUM PHARMAC. DL-001 management
8- Mr. Sandesh C. Seth M.B.A., M.S.Chairman & CEO · born 1964
- Dr. Matthew T. David M.D.CFO & Principal Financial Officer · born 1977
- Dr. Adeela Kamal Ph.D.Chief Scientific Officer · born 1971
- Dr. Paul Diamond Esq., Ph.D.Vice President of Patent & Legal Counsel
- Ms. Lynn M. Bodarky M.B.A.Chief Business Officer · born 1966
- Dr. Steffen Heeger M.D., M.Sc., Ph.D.Chief Medical Officer
- Mr. Sean Conner MaenpaaSenior Vice President of Business Development
- Dr. Madhuri Vusirikala M.D.Vice President of Clinical Development BMT & Cellular Therapy